Cargando…

Evaluation of gene amplification and protein expression of HER-2/neu in esophageal squamous cell carcinoma using Fluorescence in situ Hybridization (FISH) and immunohistochemistry

BACKGROUND: Esophageal squamous cell carcinoma (ESCC) is the sixth most frequent neoplasia in Brazil. It is usually associated with a poor prognosis because it is often at an advanced stage when diagnosed and there is a high frequency of lymph node metastases. It is important to know what prognostic...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sato-Kuwabara, Yukie, Neves, José I, Fregnani, José HTG, Sallum, Rubens A, Soares, Fernando A
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2009
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2648997/ https://www.ncbi.nlm.nih.gov/pubmed/19128465 http://dx.doi.org/10.1186/1471-2407-9-6

Ejemplares similares

Evaluation of HER-2/neu status in breast cancer specimens using immunohistochemistry (IHC) & fluorescence in-situ hybridization (FISH) assay
por: Goud, Kalal Iravathy, et al.
Publicado: (2012)

HER-2/neu Amplification Testing in Breast Cancer by Multiplex Ligation-Dependent Probe Amplification in Comparison with Immunohistochemistry and In Situ Hybridization
por: Moelans, Cathy B., et al.
Publicado: (2009)

Correlation between HER2/neu protein overexpression on Immunohistochemistry and Fluorescent in Situ Hybridization (FISH) in breast carcinoma: Problems in developing countries
por: Mukhtar, Zubaria, et al.
Publicado: (2023)

Comparison of Chromogenic In Situ Hybridisation with Fluorescence In Situ Hybridisation and Immunohistochemistry for the Assessment of Her-2/neu Oncogene in Archival Material of Breast Carcinoma
por: Pothos, Alexios, et al.
Publicado: (2008)

LED-FISH: Fluorescence microscopy based on light emitting diodes for the molecular analysis of Her-2/neu oncogene amplification
por: Lang, Dagmar S, et al.
Publicado: (2008)

Determination of the HER2 amplification status by in situ fluorescent hybridization and concordance with immunohistochemistry for breast cancer samples in Colombia
por: Plata, Adriana, et al.
Publicado: (2013)

Comparison of immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) assessment for Her-2 status in breast cancer
por: Sui, Weiguo, et al.
Publicado: (2009)

Immunohistochemistry and alternative FISH testing in breast cancer with HER2 equivocal amplification
por: Agersborg, Sally, et al.
Publicado: (2018)

Low Level of Her-2 Locus Amplification by Fluorescent In Situ Hybridization Does Not Correlate with Her-2 Protein Overexpression by Immunohistochemistry in Barrett's Esophagus
por: Rygiel, Agnieszka M., et al.
Publicado: (2010)

Correlation of Immunohistochemistry and Fluorescence in Situ Hybridization for HER-2 Assessment in Breast Cancer Patients: Single Centre Experience
por: Bogdanovska-Todorovska, Magdalena, et al.
Publicado: (2018)

Are There More HER2 FISH in the Sea? An Institution’s Experience in Identifying HER2 Positivity Using Fluorescent In Situ Hybridization in Patients with HER2 Negative Immunohistochemistry
por: Suydam, Camille, et al.
Publicado: (2023)

HER2/neu (ERBB2) expression and gene amplification correlates with better survival in esophageal adenocarcinoma
por: Plum, Patrick Sven, et al.
Publicado: (2019)

Comparison of HER2 status by fluorescence in situ hybridisation and immunohistochemistry in gastric cancer
por: Chen, Ming, et al.
Publicado: (2014)

Is HER2 amplification predictable by digital immunohistochemistry?
por: Micsik, Tamás, et al.
Publicado: (2013)

HER-2/neu oncogene: what does amplification mean?
por: Pavy, J. J., et al.
Publicado: (1993)

Detection of Her-2/neu expression in gastric cancer: Quantitative PCR versus immunohistochemistry
por: ZHU, GUANG-JUN, et al.
Publicado: (2014)

Chromogenic in Situ Hybridization Technique versus Immunohistochemistry in Assessment of HER2/neu Status in 448 Iraqi Patients with Invasive Breast Carcinoma
por: Ali, Ali Hussein Mohammed, et al.
Publicado: (2019)

Comparison of Immunohistochemical Methods (IHC) and Fluorescent in Situ Hybridization (FISH) in the Detection of HER 2 /Neu Gene in Kurdish Patients with Breast Cancer in Western Iran
por: Aznab, Mozafar, et al.
Publicado: (2022)

Real-time PCR complements immunohistochemistry in the determination of HER-2/neu status in breast cancer
por: Nistor, Andreea, et al.
Publicado: (2006)

Detection of HER-2/neu, c-myc amplification and p53 inactivation by FISH in Egyptian patients with breast cancer
por: Ismail, Manal F., et al.
Publicado: (2009)

HER2 overexpression/amplification status in colorectal cancer: a comparison between immunohistochemistry and fluorescence in situ hybridization using five different immunohistochemical scoring criteria
por: Sun, Qi, et al.
Publicado: (2022)

TOPOIIα and HER-2/neu overexpression/amplification in Barrett’s oesophagus, dysplasia and adenocarcinoma
por: Rossi, Elisa, et al.
Publicado: (2010)

Fluorescent in Situ Hybridization and Real-Time Quantitative Polymerase Chain Reaction to Evaluate HER-2/neu Status in Breast Cancer
por: Homaei Shandiz, Fatemeh, et al.
Publicado: (2017)

c-erbB-2 in astrocytomas: infrequent overexpression by immunohistochemistry and absence of gene amplification by fluorescence in situ hybridization.
por: Haapasalo, H., et al.
Publicado: (1996)

Assessment of ERBB2 and EGFR gene amplification and protein expression in gastric carcinoma by immunohistochemistry and fluorescence in situ hybridization
por: YK, Wang, et al.
Publicado: (2011)

Prognostic role of HER2 amplification based on fluorescence in situ hybridization (FISH) in pancreatic ductal adenocarcinoma (PDAC): a meta-analysis
por: Li, Xiaoping, et al.
Publicado: (2016)

HER-2/neu Oncogene Amplification by Chromogenic in situ Hybridization in 130 Breast Cancers Using Tissue Microarray and Clinical Follow-up Studies
por: Chang, Eundeok, et al.
Publicado: (2004)

Detection of HER2 Amplification in Breast Carcinomas: Comparison of Multiplex Ligation-Dependent Probe Amplification (MLPA) and Fluorescence In Situ Hybridization (FISH) combined with Automated Spot Counting
por: Moerland, Elna, et al.
Publicado: (2006)

Evaluating HER2 Gene Amplification Using Chromogenic In Situ Hybridization (CISH) Method In Comparison To Immunohistochemistry Method in Breast Carcinoma
por: Atabati, Hadi, et al.
Publicado: (2018)

Peripheral position of CCND1 and HER-2/neu oncogenes within chromosome territories in esophageal and gastric cancers non-related to amplification and overexpression
por: Bizari, Lucimari, et al.
Publicado: (2009)

Frequencies of HER-2/neu expression and gene amplification in patients with oesophageal squamous cell carcinoma
por: Mimura, K, et al.
Publicado: (2005)

HER-2/neu amplification testing in breast cancer by Multiplex Ligation-dependent Probe Amplification: influence of manual- and laser microdissection
por: Moelans, Cathy B, et al.
Publicado: (2009)

Silver-Enhanced In Situ Hybridization as an Alternative to Fluorescence In Situ Hybridization for Assaying HER2 Amplification in Clinical Breast Cancer
por: Park, Kyeongmee, et al.
Publicado: (2011)

Breast Cancer and Her-2/Neu
por: Sherwood, Roy
Publicado: (2005)

Evaluation of HER-2/neu gene amplification and protein expression in non-small cell lung carcinomas
por: Hirsch, F R, et al.
Publicado: (2002)

HER2 Amplification by Next-Generation Sequencing in Lung Carcinoma: A Comparison of NGS Amplified and Non-amplified Cases by Immunohistochemistry and In Situ Hybridization
por: Kıvrak, Hale, et al.
Publicado: (2022)

HER2 amplification by next-generation sequencing to identify HER2-positive invasive breast cancer with negative HER2 immunohistochemistry
por: Morsberger, Laura, et al.
Publicado: (2022)

Establishment of two new cell lines derived from human breast carcinomas with HER-2/neu amplification.
por: Meltzer, P., et al.
Publicado: (1991)

Her2/neu Protein Expression and Oncogene Amplification in Gastric Carcinoma with Clinico-Pathological Correlation in Egyptian Patients
por: Hadi, Ahmed Abdel, et al.
Publicado: (2016)

Chromogenic in situ hybridization compared with other approaches to evaluate HER2/neu status in breast carcinomas
por: Rosa, F.E., et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_88r131mtqslfh0acu68bgnu8sa